news & events
portfolio news
24.09.20
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
18.09.20
LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs
15.09.20
ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio
15.09.20
Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase 1 Clinical Data Presented Recently at Several Scientific Conferences
27.08.20
Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis
20.08.20
Sanifit Appoints Adam Levy as Chief Financial Officer
21.07.20
CorWave Awarded €2.5M From the European Commission Through the EIC Accelerator Program
20.07.20
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
08.07.20
VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
07.07.20
CVRx® Raises $50 Million in New Equity Financing
